Health Care Equipment

Outset Medical

Josh Jennings Maintains Buy Rating on Outset Medical

Outset Medical released FY2025 9 Months Earnings on November 10 After-Market EST, actual revenue USD 90.6 M, actual EPS USD -5.7114

Outset Medical released FY2025 Q3 earnings on November 10 After-Market EST, actual revenue USD 29.43 M (forecast USD 30.7 M), actual EPS USD -1.003 (forecast USD -1)

Outset Medical to Release FY2025 Q3 Earnings on November 10 After-Market EST, Forecast Revenue USD 30.7 M, EPS USD -1

Outset Medical released FY2025 Semi-Annual Earnings on August 6 After-Market (EST), Actual Revenue: USD 61.17 M, Actual EPS: USD -3.57

Outset Medical released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 31.42 M (forecast USD 29.41 M), actual EPS USD -1.0449 (forecast USD -1.115)

Outset Medical to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 29.41 M, EPS USD -1.115

Outset Medical Reports 2025 Second Quarter Financials

Outset Medical Inc's Short Interest Plummets

Outset Medical Executives Sell Stocks to Meet Tax Obligations

Outset Medical Inc CFO Disposes Common Stock

Outset Medical Inc Appoints Kevin O'Boyle to Board

Outset Medical released FY2025 Q1 earnings on May 7 After-Market EST, actual revenue USD 29.75 M (forecast USD 27.81 M), actual EPS USD -3.6633 (forecast USD -4.735)

Outset Medical Inc Reports Narrowed Losses and Revenue Beat Expectations

Outset Medical Reports 6% Q1 2025 Revenue Growth, Reaffirms Full-Year Guidance

Outset Medical Inc reports expected Q1 loss of 94 cents per share

Outset Medical to Release FY2025 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 27.81 M, EPS USD -4.735

Outset Medical Launches Innovative Dialysis Technology to Reduce Costs and Simplify Procedures

Outset Medical released FY2024 Q4 earnings on February 19 After-Market (EST), actual revenue USD 29.47 M (forecast USD 28.47 M), actual EPS USD -7.2915 (forecast USD -7.8)

Outset Medical released FY2024 annual earnings on February 19 After-Market (EST), actual revenue 113.69 M USD (forecast 112.68 M USD), actual EPS -36.9509 USD (forecast -37.9499 USD)

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap